Company Performance Metrics
New drugs fail in human clinical trials 90% of the time. These failures can be traced directly back to the consistent inability of preclinical animal studies to predict clinical success, yet the design process for preclinical animal studies has remained largely unchanged for decades; scientists read a tiny fraction of published literature and write
their experimental protocols in 2-4 weeks. This time-consuming, tedious process is not only a major pain point for in-vivo scientists but leads to substantial experimental design flaws, resulting in unreliable data with which billion-dollar decisions are made. At ModernVivo, we are revolutionizing this antiquated process by equipping scientists with tools that enable them to write in-vivo protocols more effectively. Our technology empowers scientists to streamline their work, accelerating drug development timelines.
